FS Development in an 8-K filing announced that shareholders have approved the SPAC’s proposed $216 million merger with Gemini Therapeutics.
The vote was 10,861,619 shares in favor of the deal with 912,082 shares voted in opposition. The SPAC said 100 shares were redeemed.
Gemini is a clinical stage precision medicine company developing treatments for genetically defined age-related macular degeneration. Read more.
